Drug Profile
Remternetug - Eli Lilly and Company
Alternative Names: LY-3372993; N3pG 4; N3PG-IVLatest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Alzheimer's disease
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease(In the elderly, In adults) in Japan (IV)
- 01 Aug 2022 Phase-III clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (SC) (NCT05463731)
- 01 Aug 2022 Phase-III clinical trials in Alzheimer's disease (In the elderly, In adults) in USA (IV) (NCT05463731)